[(pF)Phe4]Nociceptin(1-13)NH2 (TFA)

• UNSPSC Description:

  [(pF)Phe4]Nociceptin(1-13)NH2 TFA is a highly potent and selective NOP receptor (OP4) agonist, with a pKi of 10.68 and a pEC50 of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 TFA displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold)[1][2].

• Target Antigen:

  Opioid Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/pf-phe4-nociceptin-1-13-nh2-tfa.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC(C(F)(F)F)=O.FC(C=C1)=CC=C1C[C@H](NC(CNC(CNC([C@@H](N)CC2=CC=CC=C2)=O)=O)=O)C(N[C@@H]([C@H](O)C)C(NCC(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N)=O)CCCCN)=O)=O)=O)=O)=O)=O)=O)=O)=O

• Molecular Weight:

  1513.60

• References & Citations:

  [1]Guerrini R, et al. Structure-activity studies of the Phe(4) residue of nociceptin(1-13)-NH(2): identification of highly potent agonists of the nociceptin/orphanin FQ receptor. J Med Chem. 2001;44(23):3956-3964.|[2]Rizzi A, et al. Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)NH2 analogues. 2. In vivo studies. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(6):450-456.|[3]Bigoni R, et al. Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(6):442-449.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported